L M McShane

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Reporting recommendations for tumor marker prognostic studies (remark)
    L M McShane
    Biometric Research Branch, DCTD, U S National Cancer Institute, Bethesda, MD 20892, USA
    Exp Oncol 28:99-105. 2006
  2. pmc Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
    Lisa M McShane
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Room 5W130, MSC 9735, 9609 Medical Center Drive, Bethesda, MD 20892 9735, USA
    BMC Med 11:220. 2013
  3. doi request reprint Criteria for the use of omics-based predictors in clinical trials
    Lisa M McShane
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 502:317-20. 2013
  4. pmc Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
    Douglas G Altman
    Centre for Statistics in Medicine, University of Oxford, UK
    BMC Med 10:51. 2012
  5. pmc Statistical challenges in the development and evaluation of marker-based clinical tests
    Lisa M McShane
    Biometric Research Branch and Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, EPN 8126, Bethesda, MD 20892 7434, USA
    BMC Med 10:52. 2012
  6. pmc Evaluation of normalization methods for two-channel microRNA microarrays
    Yingdong Zhao
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 8:69. 2010
  7. ncbi request reprint Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network
    L M McShane
    National Cancer Institute, Bethesda, Maryland 20892 7434, USA
    Clin Cancer Res 6:1854-64. 2000
  8. pmc Epstein-Barr virus microRNAs and lung cancer
    J Koshiol
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Br J Cancer 105:320-6. 2011
  9. ncbi request reprint Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland
    J F Dorgan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7374, USA
    Cancer Epidemiol Biomarkers Prev 7:1069-74. 1998
  10. pmc Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim
    E L Korn
    Biometric Research Branch, EPN 8128, National Cancer Institute, National Institutes of Health, Bethesda MD 20892, USA
    Br J Cancer 86:1093-6. 2002

Detail Information

Publications17

  1. ncbi request reprint Reporting recommendations for tumor marker prognostic studies (remark)
    L M McShane
    Biometric Research Branch, DCTD, U S National Cancer Institute, Bethesda, MD 20892, USA
    Exp Oncol 28:99-105. 2006
    ....
  2. pmc Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
    Lisa M McShane
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Room 5W130, MSC 9735, 9609 Medical Center Drive, Bethesda, MD 20892 9735, USA
    BMC Med 11:220. 2013
    ..The US National Cancer Institute plans to refer to these guidelines for review of proposals for studies involving omics tests, and it is hoped that other sponsors will adopt the checklist as well...
  3. doi request reprint Criteria for the use of omics-based predictors in clinical trials
    Lisa M McShane
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 502:317-20. 2013
    ..The checklist will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests will be used to guide therapy. ..
  4. pmc Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
    Douglas G Altman
    Centre for Statistics in Medicine, University of Oxford, UK
    BMC Med 10:51. 2012
    ..In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report...
  5. pmc Statistical challenges in the development and evaluation of marker-based clinical tests
    Lisa M McShane
    Biometric Research Branch and Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, EPN 8126, Bethesda, MD 20892 7434, USA
    BMC Med 10:52. 2012
    ..The focus of this commentary is the many statistical challenges in translational marker research, specifically in the development and validation of marker-based tests that have clinical utility for therapeutic decision-making...
  6. pmc Evaluation of normalization methods for two-channel microRNA microarrays
    Yingdong Zhao
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Transl Med 8:69. 2010
    ..Findings from previous studies have sometimes been inconclusive or contradictory. Further studies to determine optimal normalization methods for miR microarrays are needed...
  7. ncbi request reprint Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network
    L M McShane
    National Cancer Institute, Bethesda, Maryland 20892 7434, USA
    Clin Cancer Res 6:1854-64. 2000
    ..Standardization of staining protocols and selection of a uniform threshold for binary interpretation of results may improve assay reproducibility between laboratories...
  8. pmc Epstein-Barr virus microRNAs and lung cancer
    J Koshiol
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Br J Cancer 105:320-6. 2011
    ..We conducted the first analysis of viral microRNAs (miRNAs) in lung cancer, with a focus on Epstein-Barr virus (EBV)...
  9. ncbi request reprint Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland
    J F Dorgan
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7374, USA
    Cancer Epidemiol Biomarkers Prev 7:1069-74. 1998
    ..These results do not support a strong relationship of serum androgens and estrogens with prostate cancer in smokers. Within-person variation in concentrations of some hormones may have contributed to the lack of significant associations...
  10. pmc Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim
    E L Korn
    Biometric Research Branch, EPN 8128, National Cancer Institute, National Institutes of Health, Bethesda MD 20892, USA
    Br J Cancer 86:1093-6. 2002
    ..These findings were not reported by the original investigators who analysed the data using cluster analysis techniques...
  11. ncbi request reprint Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors
    P S Albert
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892 7434, USA
    Biometrics 57:610-9. 2001
    ..These mixture models are shown to offer an improvement over other methods in a variety of settings, but we caution that, in general, care must be taken in applying latent class models...
  12. ncbi request reprint Covariate measurement error adjustment for matched case-control studies
    L M McShane
    National Cancer Institute, Biometric Research Branch, DCTD, Bethesda, Maryland 20892 7434, USA
    Biometrics 57:62-73. 2001
    ..We present an example of the procedure applied to data from a matched case-control study of prostate cancer and serum hormone levels, and we compare its performance to that of regression calibration procedures...
  13. ncbi request reprint Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans
    P Brown
    Laboratory of CNS Studies, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 4122, USA
    Transfusion 39:1169-78. 1999
    ....
  14. ncbi request reprint Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures
    A Hildesheim
    Interdisciplinary Studies Section, Environmental Epidemiology Branch, DCEG, National Cancer Institute, Bethesda, MD 20892 7374, USA
    J Immunol Methods 225:131-43. 1999
    ..In addition, various correlates of cytokine and immunoglobulin concentrations were identified...
  15. pmc REporting recommendations for tumour MARKer prognostic studies (REMARK)
    L M McShane
    US National Cancer Institute, Bethesda, MD 20892, USA
    Br J Cancer 93:387-91. 2005
    ....
  16. ncbi request reprint Measuring cell proliferation in the rectal mucosa. comparing bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) assays
    M Kulldorff
    National Cancer Institute, Bethesda, MD, USA
    J Clin Epidemiol 53:875-83. 2000
    ..When used in a clinical or epidemiological setting, it is important to take multiple biopsies at multiple time points...
  17. ncbi request reprint Questioning the utility of pooling samples in microarray experiments with cell lines
    L Lusa
    Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Int J Biol Markers 21:67-73. 2006
    ..These findings indicate that pooling samples in microarray experiments where the biological variability is expected to be small might not be helpful and could even decrease one's ability to identify differentially expressed genes...